Dr. Reddy’s to join Nomura Hyderabad meet Sep 25

Dr. Reddy’s Laboratories Limited (RDY) reports that its management will participate in an investor conference organized by Nomura in Hyderabad on September 25, 2026.

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited (RDY) reports that its management will participate in an investor conference organized by Nomura in Hyderabad on September 25, 2026. The meeting will be an in-person group meet with analyst and institutional investors, scheduled from 11:00 to 14:00 IST and is subject to change due to exigencies of the investors or the company.

Key Figures

Investor meeting date: September 25, 2026 Meeting time window: 11:00–14:00 IST Meeting organizer: Nomura

3 metrics

Investor meeting date September 25, 2026 Date of Nomura-organized investor group meeting in Hyderabad

Meeting time window 11:00–14:00 IST Scheduled duration of the in-person group meet on September 25, 2026

Meeting organizer Nomura Organizer of the Hyderabad investor conference attended by company management

Key Terms

Regulation 30, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, foreign private issuer, institutional investor, +1 more

5 terms

Regulation 30 regulatory

"Intimation under Regulation 30 of the SEBI (Listing Obligations..."

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regulatory

"under Regulation 30 of the SEBI (Listing Obligations and..."

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16..."

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

institutional investor financial

"Schedule of Analyst / Institutional Investor Meetings"

Large organizations that buy, hold and manage stocks, bonds and other investments on behalf of clients such as pension funds, insurance companies, mutual funds, endowments or wealthy individuals. Think of them as the big buckets of money in the market whose buying or selling can move prices, signal confidence in a company, and affect access to financing or governance; their actions are closely watched by other investors for clues about market trends and risk.

group meet financial

"In-Person | Group Meet | 11:00 - 14:00 IST"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor event has DR REDDYS LABORATORIES LTD (RDY) announced in this 6-K?

The company announced that management will attend a Nomura-organized investor conference in Hyderabad on September 25, 2026, holding an in-person group meeting with analysts and institutional investors from 11:00 to 14:00 IST, subject to potential schedule changes.

When and where will Dr. Reddy’s (RDY) investor meeting take place?

The meeting is scheduled for September 25, 2026, in Hyderabad. It will be an in-person session from 11:00 to 14:00 IST, organized by Nomura as part of an analyst and institutional investor conference.

Who is organizing the September 25, 2026 investor conference for RDY?

The investor conference in which Dr. Reddy’s management will participate on September 25, 2026 is organized by Nomura, and will be held in Hyderabad as an in-person group meeting with investors.

What is the nature and mode of the Dr. Reddy’s (RDY) investor meeting disclosed?

The company describes the event as an in-person Group Meet with single institution(s) or investor groups, taking place in Hyderabad on September 25, 2026 from 11:00 to 14:00 IST.

Is the schedule of the September 25, 2026 RDY investor meeting fixed?

No. Dr. Reddy’s states that the schedule of the September 25, 2026 meeting is subject to change due to any exigencies on the part of the investors or the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 01:17 PM Accepted by SEC EDGAR 09/21/2026 - 01:15 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                         Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨                         No x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated September 21, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: September 21, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com

September 21, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings

This is to inform that the Company’s management will be participating in the following investor conference with single institution(s)/ investor groups:

Date	Organized by	Location	Meeting mode	Nature of meet	Timing
25.09.2026	Nomura	Hyderabad	In-Person	Group Meet	11:00 - 14:00 IST

Please note that the schedule of the aforesaid meeting is subject to change due to any exigencies on the part of Investors / Company.

This is for your information. 

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 38.9 KB